Entity Central Index Key
Business combination recognized identifiable assets acquired and liabilities assumed purchase option.
Business combination recognized identifiable assets acquired and liabilities assumed technology.
Finite Lived Intangible Assets Amortization Expense After Year Four
Cover [Abstract]
Document Type
Document Type
Amendment Flag
Amendment Flag
Document Quarterly Report
Document Quarterly Report
Document Period End Date
Document Period End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Fiscal Period Focus
Entity Central Index Key
Current Fiscal Year End Date
Current Fiscal Year End Date
Document Transition Report
Document Transition Report
Entity File Number
Entity File Number
Entity Registrant Name
Entity Registrant Name
Entity Incorporation, State or Country Code
Entity Incorporation State Country Code
Entity Tax Identification Number
Entity Tax Identification Number
Entity Address, Address Line One
Entity Address Address Line1
Entity Address, Address Line Two
Entity Address Address Line2
Entity Address, City or Town
Entity Address City Or Town
Entity Address, State or Province
Entity Address State Or Province
Entity Address, Postal Zip Code
Entity Address Postal Zip Code
City Area Code
City Area Code
Local Phone Number
Local Phone Number
Title of 12(b) Security
Security12b Title
Trading Symbol
Trading Symbol
Security Exchange Name
Security Exchange Name
Entity Current Reporting Status
Entity Current Reporting Status
Entity Interactive Data Current
Entity Interactive Data Current
Entity Filer Category
Entity Filer Category
Entity Small Business
Entity Small Business
Entity Emerging Growth Company
Entity Emerging Growth Company
Entity Ex Transition Period
Entity Ex Transition Period
Entity Shell Company
Entity Shell Company
Entity Common Stock, Shares Outstanding
Entity Common Stock Shares Outstanding
Direct costs and expenses.
Accretion of contingent consideration.
Change in fair value of contingent consideration excluding accretion expense.
Income Statement [Abstract]
Revenues
Revenues
Operating expenses
Operating Expenses [Abstract]
Direct costs and expenses
Direct Costs And Expenses
Research and development
Research And Development Expense
Sales, marketing, general and administrative
Selling General And Administrative Expense
Accretion of contingent consideration
Accretion Of Contingent Consideration
Change in fair value of contingent consideration
Change In Fair Value Of Contingent Consideration Excluding Accretion Expense
Total operating expenses
Operating Expenses
Loss from operations
Operating Income Loss
Interest expense
Interest Expense
Other income, net
Other Nonoperating Income Expense
Net loss
Net Income Loss
Net loss per share, basic and diluted
Earnings Per Share Basic And Diluted
Weighted-average shares outstanding, basic and diluted
Weighted Average Number Of Share Outstanding Basic And Diluted
Put option liability current.
Paycheck protection program note payable non-current.
Statement Of Financial Position [Abstract]
Assets
Assets [Abstract]
Current assets
Assets Current [Abstract]
Cash and cash equivalents
Cash And Cash Equivalents At Carrying Value
Accounts receivable
Accounts Receivable Net Current
Other current assets
Other Assets Current
Total current assets
Assets Current
Non‑current assets
Assets Noncurrent [Abstract]
Property and equipment, net
Property Plant And Equipment Net
Intangible assets, net
Intangible Assets Net Excluding Goodwill
Deposits
Deposits Assets Noncurrent
Goodwill
Goodwill
Total non‑current assets
Assets Noncurrent
Total assets
Assets
Liabilities and Stockholders' Deficit
Liabilities And Stockholders Equity [Abstract]
Current liabilities
Liabilities Current [Abstract]
Accounts payable
Accounts Payable Current
Accrued liabilities
Accrued Liabilities Current
Deferred revenue
Contract With Customer Liability Current
Convertible notes payable
Convertible Notes Payable Current
Current portion of note payable
Notes Payable To Bank Current
Put option liability
Put Option Liability Current
Total current liabilities
Liabilities Current
Non‑current liabilities
Liabilities Noncurrent [Abstract]
Warrant liability
Warrants And Rights Outstanding
Other liabilities
Other Liabilities Noncurrent
Long‑term notes payable
Long Term Notes Payable
Paycheck protection program note payable
Paycheck Protection Program Note Payable Noncurrent
Contingent consideration
Business Combination Contingent Consideration Liability Noncurrent
Total non‑current liabilities
Liabilities Noncurrent
Total liabilities
Liabilities
Commitments and contingencies
Commitments And Contingencies
Convertible Preferred stock
Temporary Equity [Abstract]
Convertible preferred stock, $0.001 par value, 185,432,719 (2020) and 174,237,067 (2019) authorized; 118,766,273 (2020 and 2019) issued and outstanding; liquidation preference of $202,582 (2020 and 2019)
Temporary Equity Carrying Amount Attributable To Parent
Stockholders' deficit
Stockholders Equity [Abstract]
Common stock, $0.001 par value, 220,000,000 (2020) and 190,000,000 (2019) authorized; 289,508 (2020) and 254,918 (2019) issued and outstanding
Common Stock Value
Additional paid‑in capital
Additional Paid In Capital
Accumulated deficit
Retained Earnings Accumulated Deficit
Total stockholders' deficit
Stockholders Equity
Total liabilities, convertible preferred stock, and stockholders' deficit
Liabilities And Stockholders Equity
Convertible preferred stock, par value
Temporary Equity Par Or Stated Value Per Share
Convertible preferred stock, authorized
Temporary Equity Shares Authorized
Convertible preferred stock, issued
Temporary Equity Shares Issued
Convertible preferred stock, outstanding
Temporary Equity Shares Outstanding
Convertible preferred stock, liquidation preference
Temporary Equity Liquidation Preference
Common stock, par value
Common Stock Par Or Stated Value Per Share
Common stock, authorized
Common Stock Shares Authorized
Common stock, issued
Common Stock Shares Issued
Common stock, outstanding
Common Stock Shares Outstanding
Statement Of Stockholders Equity [Abstract]
Statement [Table]
Statement [Table]
Class of Stock
Statement Class Of Stock [Axis]
Class of Stock
Class Of Stock [Domain]
Series A-1 Convertible Preferred Stock.
Series A-1 Convertible Preferred Stock
Series A1 Convertible Preferred Stock [Member]
Series A-2 Convertible Preferred Stock.
Series A-2 Convertible Preferred Stock
Series A2 Convertible Preferred Stock [Member]
Series A-3 Convertible Preferred Stock.
Series A-3 Convertible Preferred Stock
Series A3 Convertible Preferred Stock [Member]
Series B Convertible Preferred Stock
Series B Preferred Stock [Member]
Series B-1 Convertible Preferred Stock.
Series B-1 Convertible Preferred Stock
Series B1 Convertible Preferred Stock [Member]
Series C Convertible Preferred Stock
Series C Preferred Stock [Member]
Series D Convertible Preferred Stock
Series D Preferred Stock [Member]
Series E Convertible Preferred Stock
Series E Preferred Stock [Member]
Series F Convertible Preferred Stock
Series F Preferred Stock [Member]
Equity Components
Statement Equity Components [Axis]
Equity Component
Equity Component [Domain]
Common Stock
Common Stock [Member]
Additional Paid-in Capital
Additional Paid In Capital [Member]
Accumulated Deficit
Retained Earnings [Member]
Series G Convertible Preferred Stock
Series G Preferred Stock [Member]
Series H Convertible Preferred Stock
Series H Preferred Stock [Member]
Statement [Line Items]
Statement [Line Items]
Balances
Temporary Equity Balance, Shares
Temporary Equity Balance
Common Stock Balance, Shares
Shares Outstanding
Exercise of stock options
Stock Issued During Period Value Stock Options Exercised
Exercise of stock options, shares
Stock Issued During Period Shares Stock Options Exercised
Stock‑based compensation
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
Issuance of Series H Preferred Stock
Temporary Equity Stock Issued During Period Value New Issues
Temporary equity stock issued during period shares new issues.
Issuance of Series H Preferred Stock, shares
Temporary Equity Stock Issued During Period Shares New Issues
Net loss
Balances
Temporary Equity Balance, Shares
Temporary Equity Balance
Common Stock Balance, Shares
Temporary equity issuance costs.
Issuance costs
Temporary Equity Issuance Costs
Accrued interest on notes payable and convertible notes payable.
Payments for proceeds from patent costs and intangible asset acquisition, net.
Payments to acquire Oncimmune.
Statement Of Cash Flows [Abstract]
Cash flows from operating activities
Net Cash Provided By Used In Operating Activities [Abstract]
Net loss
Profit Loss
Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]
Depreciation and amortization
Depreciation And Amortization
Amortization of convertible notes debt discount
Amortization Of Debt Discount Premium
Stock‑based compensation expense
Share Based Compensation
Change in fair value of warrant liability
Fair Value Adjustment Of Warrants
Change in contingent consideration
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
Accrued interest on notes payable and convertible notes payable
Accrued Interest On Notes Payable And Convertible Notes Payable
Amortization of debt issuance costs
Amortization Of Financing Costs
Provision for doubtful accounts
Provision For Doubtful Accounts
Write off of assets
Asset Impairment Charges
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in acquisitions:
Increase Decrease In Operating Capital [Abstract]
Accounts receivable
Increase Decrease In Accounts Receivable
Other current assets
Increase Decrease In Other Current Assets
Other long-term assets
Increase Decrease In Other Noncurrent Assets
Accounts payable and other accrued liabilities
Increase Decrease In Accounts Payable And Accrued Liabilities
Deferred revenue
Increase Decrease In Contract With Customer Liability
Net cash and cash equivalents and restricted cash used in operating activities
Net Cash Provided By Used In Operating Activities
Cash flows from investing activities
Net Cash Provided By Used In Investing Activities [Abstract]
Purchase of property and equipment
Payments To Acquire Property Plant And Equipment
Patent costs and intangible asset acquisition, net
Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net
Payments to acquire Oncimmune
Payments To Acquire Oncimmune
Net cash and cash equivalents and restricted cash used in investing activities
Net Cash Provided By Used In Investing Activities
Cash flows from financing activities
Net Cash Provided By Used In Financing Activities [Abstract]
Proceeds from issuance of series H preferred stock
Proceeds From Issuance Of Convertible Preferred Stock
Proceeds from issuance of convertible notes payable
Proceeds From Convertible Debt
Proceeds from exercise of common stock options
Proceeds From Stock Options Exercised
Proceeds from Paycheck protection program note payable
Proceeds From Notes Payable
Other
Proceeds From Payments For Other Financing Activities
Net cash and cash equivalents and restricted cash provided by financing activities
Net Cash Provided By Used In Financing Activities
Net increase in cash and cash equivalents and restricted cash
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
Cash, cash equivalents, and restricted cash ‑ beginning of period
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
Cash, cash equivalents, and restricted cash ‑ end of period
Cash paid for income taxes
Income Taxes Paid Net
Cash paid for interest
Interest Paid Net
Value of put option recorded at issuance of convertible notes payable.
Supplemental disclosure of non cash activity
Supplemental Cash Flow Information [Abstract]
Value of put option recorded at issuance of convertible notes payable
Value Of Put Option Recorded At Issuance Of Convertible Notes Payable
Accounting Policies [Abstract]
Description of Business and Summary of Significant Accounting Policies
Business Description And Accounting Policies [Text Block]
Business Combinations [Abstract]
Business Combinations
Business Combination Disclosure [Text Block]
Fair Value Disclosures [Abstract]
Fair Value Accounting
Fair Value Disclosures [Text Block]
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Disclosures
Supplemental Balance Sheet Disclosures [Text Block]
Convertible notes payable.
Debt Disclosure [Abstract]
Convertible Notes Payable
Convertible Notes Payable [Text Block]
Long-Term Debt
Debt Disclosure [Text Block]
Income Tax Disclosure [Abstract]
Income Taxes
Income Tax Disclosure [Text Block]
Commitments And Contingencies Disclosure [Abstract]
Commitments
Commitments And Contingencies Disclosure [Text Block]
Class Of Stock Disclosures [Abstract]
Convertible Preferred Stock
Preferred Stock [Text Block]
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Options
Disclosure Of Compensation Related Costs Share Based Payments [Text Block]
Warrants for convertible preferred stock.
Warrants And Rights Note Disclosure [Abstract]
Warrants for Convertible Preferred Stock
Warrants For Convertible Preferred Stock [Text Block]
Subsequent Events [Abstract]
Subsequent Events
Subsequent Events [Text Block]
Organization and nature of operations.
Organization and Nature of Operations
Organization And Nature Of Operations Policy [Text Block]
Basis of Presentation
Basis Of Accounting Policy Policy [Text Block]
Reverse stock split and initial public offering.
Reverse Stock Split and Initial Public Offering
Reverse Stock Split And Initial Public Offering Policy [Text Block]
Use of Estimates
Use Of Estimates
Segment Information
Segment Reporting Policy Policy [Text Block]
Comprehensive Loss
Comprehensive Income Policy Policy [Text Block]
Concentration of Risk
Concentration Risk Credit Risk
Cash, Cash Equivalents, and Restricted Cash
Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy
Accounts Receivable
Trade And Other Accounts Receivable Policy
Inventory
Inventory Policy [Text Block]
Property and Equipment
Property Plant And Equipment Policy [Text Block]
Intangible Assets
Goodwill And Intangible Assets Intangible Assets Policy
Long Lived Assets
Impairment Or Disposal Of Long Lived Assets Policy [Text Block]
Deferred rent policy.
Deferred Rent
Deferred Rent Policy [Text Block]
Goodwill
Goodwill And Intangible Assets Goodwill Policy
Revenue Recognition
Revenue Recognition Policy [Text Block]
Deferred Revenue
Revenue From Contract With Customer Policy [Text Block]
Research and Development Expenses and Accrued Research and Development Expenses
Research And Development Expense Policy
Stock Based Compensation
Share Based Compensation Option And Incentive Plans Policy
Income Taxes
Income Tax Policy [Text Block]
Disclosure of accounting policy for warrant liability.
Warrant Liability
Warrant Liability Policy [Text Block]
Disclosure of accounting policy for changes in fair value of contingent consideration.
Changes in Fair Value of Contingent Consideration
Changes In Fair Value Of Contingent Consideration Policy [Text Block]
Fair Value of Financial Instruments
Fair Value Of Financial Instruments Policy
Business Combinations
Business Combinations Policy
Deferred Offering Costs
Deferred Charges Policy [Text Block]
Recently Issued Accounting Standards Not Yet Adopted
New Accounting Pronouncements Policy Policy [Text Block]
Net Loss per Share
Earnings Per Share Policy [Text Block]
Summary of Revenue from Services
Disaggregation Of Revenue Table [Text Block]
Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders
Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]
Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]
Summary of Aggregate Consideration Paid by Company and Allocation of Purchase Price
Business Combination Segment Allocation Table [Text Block]
Summary of Intangible Assets Acquired Amortization Method And Estimated Useful Lives
Schedule Of Finite Lived Intangible Assets Table [Text Block]
Schedule of Liabilities Measured at Fair Value on Recurring Basis
Fair Value Liabilities Measured On Recurring Basis [Text Block]
Schedule of Unobservable Inputs to Calculate Fair Value of Liabilities Classified as Level 3 Liabilities
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]
Schedule of Property and Equipment
Property Plant And Equipment [Text Block]
Schedule of Intangible Assets
Schedule Of Intangible Assets And Goodwill Table [Text Block]
Schedule of Amortization Related to Remaining Net Intangible Assets Schedule to Amortize
Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]
Schedule of Accrued Liabilities
Schedule Of Accrued Liabilities Table [Text Block]
Summary of convertible notes payable.
Summary of Convertible Notes Payable
Summary Of Convertible Notes Payable Table [Text Block]
Summary of Long-term Notes Payable
Schedule Of Debt Instruments [Text Block]
Summary of Maturities of Long-term Obligations
Schedule Of Maturities Of Long Term Debt Table [Text Block]
Summary of Future Minimum Lease Payments for Operating Lease Obligations, Net of Sublease Income
Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]
Schedule of Convertible Preferred Stock.
Schedule of Convertible Preferred Stock
Schedule Of Convertible Preferred Stock Table [Text Block]
Summary of Activity for Options and Restricted Stock Units (RSUs) Outstanding
Schedule Of Share Based Compensation Activity Table [Text Block]
Composition of Options Outstanding and Exercisable
Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Text Block]
Summary of Weighted Average Assumptions
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]
Impact of Employee Stock-based Compensation Expense
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]
Summary of Activity for Convertible Preferred Stock Warrants Outstanding
Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]
Description of business and summary of significant accounting policies.
Description Of Business And Summary Of Significant Accounting Policies [Abstract]
Description of business and summary of significant accounting policies.
Description of business and summary of significant accounting policies.
Description Of Business And Summary Of Significant Accounting Policies [Table]
Description Of Business And Summary Of Significant Accounting Policies [Table]
Sale of Stock
Subsidiary Sale Of Stock [Axis]
Sale of Stock
Sale Of Stock Name Of Transaction [Domain]
IPO
I P O [Member]
Subsequent Event Type
Subsequent Event Type [Axis]
Subsequent Event Type
Subsequent Event Type [Domain]
Subsequent Event
Subsequent Event [Member]
Customer
Major Customers [Axis]
Customer
Name Of Major Customer [Domain]
Customer one.
Customer One
Customer One [Member]
Concentration Risk Benchmark
Concentration Risk By Benchmark [Axis]
Concentration Risk Benchmark
Concentration Risk Benchmark [Domain]
Accounts Receivable
Accounts Receivable [Member]
Product and Service
Product Or Service [Axis]
Product and Service
Products And Services [Domain]
Diagnostic tests.
Diagnostic Tests
Diagnostic Tests [Member]
Concentration Risk Type
Concentration Risk By Type [Axis]
Concentration Risk Type
Concentration Risk Type [Domain]
Customer Concentration Risk
Customer Concentration Risk [Member]
Cash and Cash Equivalents
Cash And Cash Equivalents [Axis]
Cash and Cash Equivalents
Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]
Money Market Funds
Money Market Funds [Member]
Balance Sheet Location
Balance Sheet Location [Axis]
Balance Sheet Location
Balance Sheet Location [Domain]
Other Current Assets
Other Current Assets [Member]
Statistical Measurement
Range [Axis]
Statistical Measurement
Range [Member]
Minimum
Minimum [Member]
Maximum
Maximum [Member]
Finite-Lived Intangible Assets by Major Class
Finite Lived Intangible Assets By Major Class [Axis]
Finite-Lived Intangible Assets, Major Class Name
Finite Lived Intangible Assets Major Class Name [Domain]
Patent
Patents [Member]
Developed Technology
Technology Based Intangible Assets [Member]
Two service customers.
Two Service Customers
Two Service Customers [Member]
Health care provider.
Health Care Provider
Health Care Provider [Member]
Diagnostic test revenue.
Diagnostic Test Revenue
Diagnostic Test Revenue [Member]
Service revenue.
Service Revenue
Service Revenue [Member]
Testing services.
Testing Services
Testing Services [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Accumulated deficit
Stockholders’ deficit
Net proceeds
Proceeds From Issuance Initial Public Offering
Convertible preferred stock and convertible notes payable converted to common stock.
Reverse stock split, description
Stockholders Equity Reverse Stock Split
Reverse stock split ratio
Stockholders Equity Note Stock Split Conversion Ratio1
Shares of common stock issued and sold
Stock Issued During Period Shares New Issues
Common stock price per share
Shares Issued Price Per Share
Convertible preferred stock and convertible notes payable converted into shares of common stock
Convertible Preferred Stock And Convertible Notes Payable Converted To Common Stock
Number of operating segments
Number Of Operating Segments
Comprehensive loss
Comprehensive Income Net Of Tax
Concentration risk, percentage
Concentration Risk Percentage1
Restricted cash
Restricted Cash
Allowance for doubtful accounts
Allowance For Doubtful Accounts Receivable
Inventory balances
Inventory Net
Property, plant and equipment, useful Lives
Property Plant And Equipment Useful Life
Finite-lived intangible asset, useful life
Finite Lived Intangible Asset Useful Life
Impairment of long-lived assets
Impairment Of Long Lived Assets Held For Use
Goodwill impairments loss
Goodwill Impairment Loss
Revenues [Abstract]
Disaggregation Of Revenue [Table]
Disaggregation Of Revenue [Table]
Services
Service [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation Of Revenue [Line Items]
Deferred offering costs
Deferred Offering Costs
Earnings Per Share Basic And Diluted Other Disclosures [Abstract]
Numerator
Net Income Loss [Abstract]
Net loss attributable to common stockholders
Denominator
Earnings Per Share [Abstract]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Antidilutive Securities
Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]
Antidilutive Securities, Name
Antidilutive Securities Name [Domain]
Options to purchase common stock.
Options to Purchase Common Stock
Options To Purchase Common Stock [Member]
Warrants
Warrant [Member]
Restricted Stock Units
Restricted Stock Units R S U [Member]
Convertible Debt
Convertible Debt Securities [Member]
Convertible Preferred Stock
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
Schedule Of Business Acquisitions By Acquisition [Table]
Schedule Of Business Acquisitions By Acquisition [Table]
License Rights
License [Member]
Business Acquisition
Business Acquisition [Axis]
Business Acquisition, Acquiree
Business Acquisition Acquiree [Domain]
Oncimmune Limited.
Oncimmune Limited
Oncimmune Limited [Member]
Geographical
Statement Geographical [Axis]
Geographical
Segment Geographical [Domain]
United States
UNITED STATES
Integrated Diagnostics, Inc.
Integrated Diagnostics, Inc
Integrated Diagnostics Inc [Member]
Business Acquisition [Line Items]
Business Acquisition [Line Items]
Total consideration amount
Business Combination Consideration Transferred1
Business acquisition description
Business Acquisition Description Of Acquired Entity
Payments to acquire license rights
Other Payments To Acquire Businesses
Cash
Payments To Acquire Businesses Gross
Preferred stock issued - 10,694,904 shares
Business Combination Consideration Transferred Other1
Contingent consideration
Business Combination Consideration Transferred Liabilities Incurred
Total fair value of consideration transferred
Deposit
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Marketable Securities
Prepaid expenses and other assets
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
Inventory
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory
Property and equipment
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
Purchase option
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Purchase Option
Technology
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Technology
Accrued liabilities
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable
Liabilities
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
Total
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
Shares deposited in an escrow account.
Preferred stock issued
Preferred Stock Shares Issued
Contingent consideration fair value
Contingent Consideration Classified As Equity Fair Value Disclosure
Shares issued
Shares Issued
Shares deposited in an escrow account
Shares Deposited In Escrow Account
Business acquisition contingent consideration gross margin target period.
Business acquisition contingent consideration number of installments.
Business combination contingent consideration shares.
Business acquisition contingent consideration gross margin target
Cash Acquired From Acquisition
Business acquisition contingent consideration gross margin target period
Business Acquisition Contingent Consideration Gross Margin Target Period
Contingent consideration number of installments
Business Acquisition Contingent Consideration Number Of Installments
Undiscounted contingent consideration payment
Payments To Acquire Businesses Net Of Cash Acquired
Contingent consideration shares
Business Combination Contingent Consideration Shares
Fair value of contingent consideration recognized
Business Combination Acquired Receivables Fair Value
Technology.
Technology
Technology [Member]
Amortization Method
Finite Lived Intangible Assets Amortization Method
Fair Value
Finitelived Intangible Assets Acquired1
Finite lived intangible assets discount rate.
Acquired technology discount rate
Finite Lived Intangible Assets Discount Rate
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
Disclosure of information about liabilities measured at fair value on recurring basis.
Fair Value Liabilities Measured On Recurring Basis [Table]
Fair Value Liabilities Measured On Recurring Basis [Table]
Measurement Frequency
Fair Value By Measurement Frequency [Axis]
Measurement Frequency
Fair Value Measurement Frequency [Domain]
Fair Value, Recurring
Fair Value Measurements Recurring [Member]
Fair Value Hierarchy and NAV
Fair Value By Fair Value Hierarchy Level [Axis]
Fair Value Hierarchy and NAV
Fair Value Measurements Fair Value Hierarchy [Domain]
Level 1
Fair Value Inputs Level1 [Member]
Level 2
Fair Value Inputs Level2 [Member]
Level 3
Fair Value Inputs Level3 [Member]
Liability Class
Fair Value By Liability Class [Axis]
Fair Value by Liability Class
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]
Warrant liability.
Warrant Liability
Warrant Liability [Member]
Contingent value rights.
Contingent Value Rights
Contingent Value Rights [Member]
Contingent consideration.
Contingent Consideration
Contingent Consideration [Member]
Put option liability.
Put Option Liability
Put Option Liability [Member]
Fair Value Liabilities Measured On Recurring Basis [Line Items]
Fair Value Liabilities Measured On Recurring Basis [Line Items]
Total liabilities
Liabilities Fair Value Disclosure
Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, exercises.
Fair value measurement with unobservable inputs reconciliation recurring basis liability, accretion.
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
Issuances
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
Additions
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
Exercises
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Exercises
Change in fair value
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
Accretion
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Accretion
Payments
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
Ending balance
Calculated number of contingent value rights received by investors, if financing raised exceed the amount.
Contingent value right, percentage multiplier.
Contingent value rights shares.
Contingent value rights.
Net proceeds percentage of cash payment to the cvr holders.
Percentage of development and regulatory costs exercised using opt-out right.
Development and regulatory costs payable.
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Counterparty Name
Counterparty Name [Axis]
Counterparty Name
Repurchase Agreement Counterparty Name [Domain]
Aveo oncology.
AVEO Oncology
A V E O Oncology [Member]
Industry Sector
Equity Securities By Industry [Axis]
Industry Sector
Equity Securities Industry [Member]
Drug ficlatuzumab.
Drug Ficlatuzumab
Drug Ficlatuzumab [Member]
Series F Preferred Stock
Minimum
Maximum
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Calculated number of contingent value rights received by investors, if financing raised exceed the amount
Calculated Number Of Contingent Value Rights Received By Investors If Financing Raised Exceed Amount
Contingent value right, percentage multiplier
Contingent Value Right Percentage Multiplier
Contingent value rights shares
Contingent Value Rights Shares
Contingent value rights
Contingent Value Rights
Net proceeds percentage of cash payment to the CVR holders
Net Proceeds Percentage Of Cash Payment To C V R Holders
Percentage of development and regulatory costs exercised using opt-out right
Percentage Of Development And Regulatory Costs Exercised Using Opt Out Right
Development and regulatory costs payable
Development And Regulatory Costs Payable
Fair value of contingent consideration recognized on acquisition date
Business combination, contingent consideration arrangements, change in amount of contingent consideration, liability due to the impact of the deceleration of expected revenue and decreases in expected costs.
Business combination, contingent consideration arrangements, change in amount of contingent consideration, liability resulting from accretion of liability offset.
Business combination, contingent consideration arrangements, change in amount of contingent consideration, liability resulting from the impact of the acceleration of expected revenue and decreases in expected costs.
Business combination, contingent consideration arrangements, change in amount of contingent consideration, liability resulting from accretion of liability.
Change in contingent consideration resulting from the accretion of the liability offset
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability Resulting From Accretion Of Liability Offset
Change in contingent consideration due to the impact of the deceleration of expected revenue and decreases in expected costs
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability Due To Impact Of Deceleration Of Expected Revenue And Decreases In Expected Costs
Change in contingent consideration
Change in contingent consideration resulting from the impact of the acceleration of expected revenue and decreases in expected costs
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability Resulting From Impact Of Acceleration Of Expected Revenue And Decreases In Expected Costs
Change in contingent consideration resulting from accretion of liability
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability Resulting From Accretion Of Liability
Percentage of probabilities of contingent consideration successful achievement milestone discount rates range.
Percentage of probabilities of contingent consideration successful achievement milestone discount rates range
Percentage Of Probabilities Of Contingent Consideration Successful Achievement Milestone Discount Rates Range
Schedule Of Property Plant And Equipment [Table]
Schedule Of Property Plant And Equipment [Table]
Long-Lived Tangible Asset
Property Plant And Equipment By Type [Axis]
Long-Lived Tangible Asset
Property Plant And Equipment Type [Domain]
Lab Equipment
Equipment [Member]
Leasehold Improvements
Leasehold Improvements [Member]
Computer Equipment
Computer Equipment [Member]
Furniture and Fixtures
Furniture And Fixtures [Member]
Software
Software And Software Development Costs [Member]
Construction in Process
Construction In Progress [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment [Line Items]
Property and equipment, gross
Property Plant And Equipment Gross
Less accumulated depreciation
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
Total property and equipment
Depreciation expense
Depreciation
Schedule Of Finite Lived Intangible Assets [Table]
Schedule Of Finite Lived Intangible Assets [Table]
Purchased technology.
Purchased Technology
Purchased Technology [Member]
Purchase option.
Purchase Option
Purchase Option [Member]
Finite Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross
Finite Lived Intangible Assets Gross
Less accumulated amortization
Finite Lived Intangible Assets Accumulated Amortization
Finite-lived intangible assets, net
Finite Lived Intangible Assets Net
Trademarks (indefinite life)
Indefinite Lived Trademarks
Total intangible assets
Amortization expense
Amortization Of Intangible Assets
Remainder of 2020
Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
2021
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
2022
Finite Lived Intangible Assets Amortization Expense Year Two
2023
Finite Lived Intangible Assets Amortization Expense Year Three
2024
Finite Lived Intangible Assets Amortization Expense Year Four
Thereafter
Finite Lived Intangible Assets Amortization Expense After Year Four
Accrued clinical trial expense current.
Compensation related accruals
Employee Related Liabilities Current
Accrued clinical trial expense
Accrued Clinical Trial Expense Current
Other expenses
Other Accrued Liabilities Current
Warrant liability, current
Product Warranty Accrual Classified Current
Total accrued liabilities
Percentage of conversion price per share of convertible preferred stock.
Percentage of conversion price per share of common stock.
Debt instrument maturity date extended.
Schedule Of Short Term Debt [Table]
Schedule Of Short Term Debt [Table]
Short-term Debt, Type
Short Term Debt Type [Axis]
Short-term Debt, Type
Short Term Debt Type [Domain]
March two thousand and twenty convertible notes.
March 2020 Notes
March Two Thousand And Twenty Convertible Notes [Member]
Debt Instrument, Redemption, Period
Debt Instrument Redemption Period [Axis]
Debt Instrument, Redemption, Period
Debt Instrument Redemption Period [Domain]
First Tranche
Debt Instrument Redemption Period One [Member]
Second Tranche
Debt Instrument Redemption Period Two [Member]
December two thousand and nineteen convertible notes.
December 2019 Notes
December Two Thousand And Nineteen Convertible Notes [Member]
August two thousand and nineteen convertible notes.
August 2019 Notes
August Two Thousand And Nineteen Convertible Notes [Member]
Short Term Debt [Line Items]
Short Term Debt [Line Items]
Convertible notes payable
Notes Issued1
Convertible notes, maturity date
Debt Instrument Maturity Date
Extended debt instrument date
Debt Instrument Maturity Date Extended
Interest rate
Debt Instrument Interest Rate Stated Percentage
Conversion rate
Debt Conversion Converted Instrument Rate
Conversion price
Debt Instrument Convertible Conversion Price1
Percentage of conversion price per share of preferred stock
Percentage Of Conversion Price Per Share Of Convertible Preferred Stock
Estimated value of put option liability
Unamortized debt discount
Debt Instrument Unamortized Discount
Debt instrument converted to common stock
Stock Issued During Period Shares Conversion Of Convertible Securities
Percentage of conversion price per share of common stock
Percentage Of Conversion Price Per Share Of Common Stock
Increase to put option liability.
Increase to put option liability
Increase To Put Option Liability
Accrued interest
Interest Payable Current
Unamortized debt discount
Debt Instrument Unamortized Discount Current
Debt Instrument [Table]
Debt Instrument [Table]
Long-term Debt, Type
Longterm Debt Type [Axis]
Long-term Debt, Type
Longterm Debt Type [Domain]
PPP loan.
PPP Loan
P P P Loan [Member]
Debt Instrument
Debt Instrument [Axis]
Debt Instrument, Name
Debt Instrument Name [Domain]
CARES act.
CARES Act
C A R E S Act [Member]
Investment Type
Investment Type [Axis]
Investments
Investment Type Categorization [Member]
Interest-bearing Deposits
Interest Bearing Deposits [Member]
Notes payable 2018 notes.
2018 Notes
Notes Payable2018 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument [Line Items]
Loan principle amount
Debt Instrument Carrying Amount
Loan description
Debt Instrument Description
Payroll costs excludes compensation of an employee.
Percentage for non-payroll costs.
Upper limit of employee salary to reduce forgiveness.
Percentage of upper limit of employee salary to reduce forgiveness.
Payroll costs excludes compensation of an employee
Payroll Costs Excludes Compensation Of Employee
Percentage for non-payroll costs
Percentage For Non Payroll Costs
Upper limit of employee salary to reduce forgiveness
Upper Limit Of Employee Salary To Reduce Forgiveness
Percentage of upper limit of employee salary to reduce forgiveness
Percentage Of Upper Limit Of Employee Salary To Reduce Forgiveness
Debt instrument, fee percentage.
Debt instrument, percentage of stated interest rate, paid in cash.
Debt instrument, percentage of stated interest rate added to principal value of notes payable.
Debt instrument interest added to principal value.
Maturity date, description
Percentage of facility fee
Debt Instrument Fee Percentage
Facility fee amount
Debt Instrument Fee Amount
Warrant issued to purchase shares
Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
Fair value of warrants issued
Warrants Not Settleable In Cash Fair Value Disclosure
Percentage of interest rate, paid in cash
Debt Instrument Percentage Of Stated Interest Rate Paid In Cash
Percentage of interest rate added to principal value of notes payable
Debt Instrument Percentage Of Stated Interest Rate Added To Principal Value Of Notes Payable
Frequency of periodic payment
Debt Instrument Frequency Of Periodic Payment
Interest added to principal value
Debt Instrument Interest Added To Principal Value
Debt instrument prepayment penalty percentage.
Debt instrument back-end facility fee percentage.
Debt instrument additional interest expense fee percentage.
Debt instrument, prepayment penalty
Debt Instrument Prepayment Penalty Percentage
Debt instrument, back-end facility fee
Debt Instrument Back End Facility Fee Percentage
Debt instrument, additional interest expense fee
Debt Instrument Additional Interest Expense Fee Percentage
Early amortization of loan payment schedule
Debt Instrument Convertible Remaining Discount Amortization Period1
Debt instrument, default amount
Debt Default Longterm Debt Amount
Debt Instruments [Abstract]
2018 Notes
Other
Other Notes Payable
Unamortized debt discount and debt issuance costs
Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
Notes payable, total
Notes Payable
Less: current maturities
Notes Payable Current
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
Maturities Of Long Term Debt [Abstract]
Remainder of 2020
Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
2021
Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
2022
Long Term Debt Maturities Repayments Of Principal In Year Two
2023
Long Term Debt Maturities Repayments Of Principal In Year Three
2024
Long Term Debt Maturities Repayments Of Principal In Year Four
Thereafter
Long Term Debt Maturities Repayments Of Principal After Year Four
Long-term debt
Long Term Debt
Exercise price
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
Provision for income taxes
Income Tax Expense Benefit
Loss Contingencies [Table]
Loss Contingencies [Table]
Bdx004.
BDX004
B D X004 [Member]
Ficlatuzumab.
Ficlatuzumab
Ficlatuzumab [Member]
Nsclc poc trial.
NSCLC POC Trial
N S C L C P O C Trial [Member]
Poc clinical trials.
POC Clinical Trials
P O C Clinical Trials [Member]
Scenario
Statement Scenario [Axis]
Scenario
Scenario Unspecified [Domain]
Scenario
Scenario Forecast [Member]
Bio-rad license.
Bio-Rad License
Bio Rad License [Member]
Collaborative Arrangement and Arrangement Other than Collaborative
Type Of Arrangement [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Arrangements And Nonarrangement Transactions [Member]
Revenue share agreement.
Revenue Share Agreement
Revenue Share Agreement [Member]
Loss Contingencies [Line Items]
Loss Contingencies [Line Items]
Rent expense
Operating Leases Rent Expense Net
Leases [Abstract]
Remainder of 2020
Operating Leases Future Minimum Payments Remainder Of Fiscal Year
2021
Operating Leases Future Minimum Payments Due In Two Years
2022
Operating Leases Future Minimum Payments Due In Three Years
2023
Operating Leases Future Minimum Payments Due In Four Years
2024
Operating Leases Future Minimum Payments Due In Five Years
Thereafter
Operating Leases Future Minimum Payments Due Thereafter
Total
Operating Leases Future Minimum Payments Due
Percentage of development and regulatory costs.
Responsible percentage of development and regulatory costs
Percentage Of Development And Regulatory Costs
Remaining estimated obligation.
Percentage of royalty payments on net sales.
Percentage of license income generated from licensing.
Remaining estimated obligation
Remaining Estimated Obligation
Percentage of royalty payments on net sales
Percentage Of Royalty Payments On Net Sales
Percentage of license income generated from licensing
Percentage Of License Income Generated From Licensing
Percentage of royalty payments on net revenue.
License agreement expiry date.
Percentage of royalty payments on net revenue
Percentage Of Royalty Payments On Net Revenue
License expiry date
License Agreement Expiry Date
Royalty expense
Royalty Expense
Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests.
Minimum annual volume percentage thereafter.
Revenue share expenses.
Period of escalations of sales.
Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests
Percentage Of Revenue Share Payment Related To Acquired Diagnostic Test Recognized Revenue For Non Screening Tests
Minimum annual volume percentage thereafter
Minimum Annual Volume Percentage Thereafter
Period of escalations of sales
Period Of Escalations Of Sales
Revenue share expenses
Revenue Share Expenses
Royalty payments
Payments For Royalties
Schedule Of Stock By Class [Table]
Schedule Of Stock By Class [Table]
Series H
Series G
Series E
Series D
Series C
Series B‑1
Series B
Series A‑3
Series A‑2
Series A‑1
Class Of Stock [Line Items]
Class Of Stock [Line Items]
Shares Authorized
Shares Issued
Shares Outstanding
Defined Original Issue Price
Liquidation Preference
Nonmonetary Transaction Type
Nonmonetary Transaction Type [Axis]
Nonmonetary Transaction Type
Nonmonetary Transaction Type [Domain]
Reverse stock split.
Reverse Stock Split
Reverse Stock Split [Member]
Combined Series B.
Combined Series B
Combined Series B Preferred Stock [Member]
Series A
Series A Preferred Stock [Member]
Conversion price of preferred stock.
Preferred stock conversion rate.
Conversion of stocks, description
Conversion Of Stock Description
Preferred stock conversion price
Conversion Price Of Preferred Stock
Preferred stock conversion rate
Preferred Stock Conversion Rate
Preferred stock dividends rate
Preferred Stock Dividend Rate Percentage
Preferred stock, voting rights
Preferred Stock Voting Rights
Percentage of outstanding share holders required for automatic stock conversion.
Preferred stock, redemption terms
Preferred Stock Redemption Terms
Percentage of outstanding share holders required for automatic stock conversion
Percentage Of Outstanding Share Holders Required For Automatic Stock Conversion
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Plan Name
Plan Name [Axis]
Plan Name
Plan Name [Domain]
2006 Plan.
2006 Plan
Two Thousand Six Plan [Member]
2016 Plan.
2016 Plan
Two Thousand And Sixteen Plan [Member]
Award Type
Award Type [Axis]
Award Type
Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]
Stock options outside 2006 Plan.
Stock Options Outside 2006 Plan
Stock Options Outside2006 Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
Options granted termination period
Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
Additional stock awards granted
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
RSUs
Stock Options, Outstanding ‑ December 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
Stock Options, Granted
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
Stock Options, Forfeited/canceled
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
Stock Options, Exercised
Stock Options, Outstanding ‑ September 30, 2020
Weighted Average Exercise Price, Outstanding ‑ December 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
Weighted Average Exercise Price, Granted
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
Weighted Average Exercise Price, Forfeited/canceled
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
Weighted Average Exercise Price, Exercised
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding ‑ September 30, 2020
Share based compensation arrangement by share based payment award equity instruments other than options exercised in period.
RSUs, Outstanding ‑ December 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
RSUs, Granted
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
RSUs, Forfeited/canceled
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
RSUs, Exercised
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period
RSUs, Outstanding ‑ September 30, 2020
Share based compensation arrangement by share based payment award equity instruments other than options exercised weighted average grant date fair value.
Weighted Average Grant Date Value Per Share, Outstanding ‑ December 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
Weighted Average Grant Date Value Per Share, Granted
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
Weighted Average Grant Date Value Per Share, Forfeited/canceled
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
Weighted Average Grant Date Value Per Share, Exercised
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Weighted Average Grant Date Fair Value
Weighted Average Grant Date Value Per Share, Outstanding ‑ September 30, 2020
Share-based payment arrangement, option, exercise price.
Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table]
Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table]
Exercise Price Range
Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Axis]
Exercise Price Range
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]
Exercise price range one.
$0.42 - $0.83
Exercise Price Range One [Member]
Exercise price range two.
$2.61 - $3.74
Exercise Price Range Two [Member]
Exercise price range three.
$4.39 - $4.45
Exercise Price Range Three [Member]
Exercise price range four.
$6.83
Exercise Price Range Four [Member]
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise Prices, Lower Range Limit
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
Exercise Prices, Upper Range Limit
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
Exercise Prices
Share Based Payment Arrangement Option Exercise Price
Options Outstanding, Number
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
Option Outstanding, Price
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
Options Outstanding, Life (years)
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
Options Exercisable, Number
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
Options Exercisable, Price
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
Restricted stock units outstanding
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
Restricted stock units vested
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]
Approximate risk‑free rate
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
Average expected life
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
Dividend yield
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
Volatility
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
Estimated fair value of total options granted
Stock Granted During Period Value Sharebased Compensation
Share-based compensation, net of estimated forfeitures percentage.
Net of estimated forfeitures percentage
Share Based Compensation Net Of Estimated Forfeitures Percentage
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Income Statement Location
Income Statement Location [Axis]
Income Statement Location
Income Statement Location [Domain]
Research and Development
Research And Development Expense [Member]
Sales, Marketing, General and Administrative
Selling General And Administrative Expenses [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense
Allocated Share Based Compensation Expense
Unrecognized remaining stock based compensation balance
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
Amortization period
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
Stock options issued
Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
Expected term
Options outstanding and exercisable
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
Weighted average exercise price
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
Weighted average remaining life
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
Share-based compensation arrangement by share-based payment award equity instruments non-options outstanding weighted average remaining contractual terms.
Class Of Warrant Or Right [Table]
Class Of Warrant Or Right [Table]
Class of Warrant or Right
Class Of Warrant Or Right [Axis]
Class of Warrant or Right
Class Of Warrant Or Right [Domain]
Series E convertible preferred stock warrants.
Series E Convertible Preferred Stock Warrants
Series E Convertible Preferred Stock Warrants [Member]
Series G convertible preferred stock warrants.
Series G Convertible Preferred Stock Warrants
Series G Convertible Preferred Stock Warrants [Member]
Class Of Warrant Or Right [Line Items]
Class Of Warrant Or Right [Line Items]
Outstanding ‑ December 31, 2019, warrants
Granted, warrants
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
Forfeited/canceled, warrants
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures
Exercised, warrants
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
Outstanding ‑ September 30, 2020, warrants
Weighted average remaining contractual life at September 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Non Options Outstanding Weighted Average Remaining Contractual Terms
Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price.
Share based compensation arrangements by share based payment award non options grants in period weighted average exercise price.
Share based compensation arrangement by share based payment award non-options forfeitures and expirations in period weighted average exercise price.
Share based compensation arrangements by share based payment award non options exercises in period weighted average exercise price.
Weighted average exercise price, Outstanding ‑ December 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
Weighted average exercise price, Granted
Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price
Weighted average exercise price, Forfeited/canceled
Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Exercise Price
Weighted average exercise price, Exercised
Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price
Weighted average exercise price,Outstanding ‑ September 30, 2020